Role of peroxisome proliferator-activated receptor- γ in vascular inflammation

International Journal of Vascular Medicine

Volumn 2012, Issue , 2012, Pages

  Ohshima, Kousei ^a   Mogi, Masaki ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CIGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TROGLITAZONE;

ADIPOCYTE; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; B LYMPHOCYTE; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; DENDRITIC CELL; GLYCEMIC CONTROL; HUMAN; IMMUNE SYSTEM; LIPID METABOLISM; MACROPHAGE; MONOCYTE; NEUTROPHIL; NONHUMAN; REVIEW; T LYMPHOCYTE; VASCULITIS;

EID: 84866164346     PISSN: 20902824     EISSN: 20902832     Source Type: Journal    
DOI: 10.1155/2012/508416     Document Type: Review

References (110)

1. Ross R., Atherosclerosisan inflammatory disease. The New England Journal of Medicine 1999 340 2 115 126 2-s2.0-0033552883 10.1056/NEJM199901143400207 (Pubitemid 29054847)
2. Evans R. M., Barish G. D., Wang Y. X., PPARs and the complex journey to obesity. Nature Medicine 2004 10 4 355 361 2-s2.0-1942518840 10.1038/nm1025 (Pubitemid 38508511)
3. Marx N., Duez H., Fruchart J. C., Staels B., Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circulation Research 2004 94 9 1168 1178 2-s2.0-2442711384 10.1161/01.RES.0000127122.22685.0A (Pubitemid 38656403)
4. Berger J. P., Akiyama T. E., Meinke P. T., PPARs: therapeutic targets for metabolic disease. Trends in Pharmacological Sciences 2005 26 5 244 251 2-s2.0-18044376795 10.1016/j.tips.2005.03.003 (Pubitemid 40603072)
5. Yu S., Reddy J. K., Transcription coactivators for peroxisome proliferator-activated receptors. Biochimica et Biophysica Acta 2007 1771 8 936 951 2-s2.0-34547604561 10.1016/j.bbalip.2007.01.008 (Pubitemid 47198542)
6. Zoete V., Grosdidier A., Michielin O., Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochimica et Biophysica Acta 2007 1771 8 915 925 2-s2.0-34547661571 10.1016/j.bbalip.2007.01.007 (Pubitemid 47208545)
7. Desvergne B., Wahli W., Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Reviews 1999 20 5 649 688 2-s2.0-0033305213 (Pubitemid 30650602)
8. Rangwala S. M., Lazar M. A., Peroxisome proliferator-activated receptor γ in diabetes and metabolism. Trends in Pharmacological Sciences 2004 25 6 331 336 2-s2.0-2542491213 10.1016/j.tips.2004.03.012 (Pubitemid 38692426)
9. Lehrke M., Lazar M. A., The many faces of PPAR γ Cell 2005 123 6 993 999 2-s2.0-28944446431 10.1016/j.cell.2005.11.026 (Pubitemid 41785415)
10. Rong J. X., Qiu Y., Hansen M. K., Zhu L., Zhang V., Xie M., Okamoto Y., Mattie M. D., Higashiyama H., Asano S., Strum J. C., Ryan T. E., Adipose mitochondrial biogenesis is suppressed in db/db and high-fat diet-fed mice and improved by rosiglitazone. Diabetes 2007 56 7 1751 1760 2-s2.0-34347391646 10.2337/db06-1135 (Pubitemid 47025441)
11. Engstrom L. W., Bober L., Chen S. C., Fine J. S., Li Y., Stanton M. C., Kinsley D., Cui L., Jackson J. V., Rojas-Triana A., Lundell D., Laverty M., Gustafson E. L., Jenh C. H., Kowalski T. J., Manfra D. J., Kinetic assessment and therapeutic modulation of metabolic and inflammatory profiles in mice on a high-fat and cholesterol diet. PPAR Research 2010 2010 13 2-s2.0-77952483593 10.1155/2010/970164 970164
12. Song G. Y., Gao Y., Wang C., Hu S. G., Wang J., Qu D. M., Ma H. J., Rosiglitazone reduces fatty acid translocase and increases AMPK in skeletal muscle in aged rats: a possible mechanism to prevent high-fat-induced insulin resistance. Chinese Medical Journal 2010 123 17 2384 2391 2-s2.0-79851487913 10.3760/cma.j.issn.0366-6999.2010.17.019
13. Foryst-Ludwig A., Hartge M., Clemenz M., Sprang C., He K., Marx N., Unger T., Kintscher U., PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovascular Diabetology 2010 9, article 64 2-s2.0-77957919796 10.1186/1475-2840-9-64
14. Dormandy J. A., Charbonnel B., Eckland D. J., Erdmann E., Massi-Benedetti M., Moules I. K., Skene A. M., Tan M. H., Lefèbvre P. J., Murray G. D., Standl E., Wilcox R. G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R. J., Korányi L., Laakso M., Moká M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Škrha J., Smith U., Tato J., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. The Lancet 2005 366 9493 1279 1289 2-s2.0-26244453309 10.1016/S0140-6736(05)67528-9 (Pubitemid 41416583)
15. Gerstein H. C., Yusuf S., Bosch J., Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. The Lancet 2006 368 9541 1096 1105 10.1016/S0140-6736(06)69420-8 (Pubitemid 44402668)
16. Kahn S. E., Haffner S. M., Heise M. A., Herman W. H., Holman R. R., Jones N. P., Kravitz B. G., Lachin J. M., O'Neill M. C., Zinman B., Viberti G., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. The New England Journal of Medicine 2006 355 23 2427 2443 2-s2.0-33845405222 10.1056/NEJMoa066224 (Pubitemid 44903747)
17. Nissen S. E., Nicholls S. J., Wolski K., Nesto R., Kupfer S., Perez A., Jure H., de Larochellière R., Staniloae C. S., Mavromatis K., Saw J., Hu B., Lincoff A. M., Tuzcu E. M., Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. Journal of the American Medical Association 2008 299 13 1561 1573 2-s2.0-41649084422 10.1001/jama.299.13.1561 (Pubitemid 351482795)
18. Kanda T., Brown J. D., Orasanu G., Vogel S., Gonzalez F. J., Sartoretto J., Michel T., Plutzky J., PPAR γ in the endothelium regulates metabolic responses to high-fat diet in mice. Journal of Clinical Investigation 2009 119 1 110 124 2-s2.0-61749083559 10.1172/JCI36233
19. Kleinhenz J. M., Kleinhenz D. J., You S., Ritzenthaler J. D., Hansen J. M., Archer D. R., Sutliff R. L., Hart C. M., Disruption of endothelial peroxisome proliferator-activated receptor- γ reduces vascular nitric oxide production. American Journal of Physiology 2009 297 5 H1647 H1654 2-s2.0-70350433697 10.1152/ajpheart.00148.2009
20. Qu A., Shah Y. M., Manna S. K., Gonzalez F. J., Disruption of endothelial peroxisome proliferator-activated receptor gamma accelerates diet-induced atherogenesis in LDL receptor-null mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 1 65 73
21. Wang N., Verna L., Chen N. G., Chen J., Li H., Forman B. M., Stemerman M. B., Constitutive activation of peroxisome proliferator-activated receptor- γ suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. The Journal of Biological Chemistry 2002 277 37 34176 34181 2-s2.0-0037072826 10.1074/jbc.M203436200
22. Straus D. S., Glass C. K., Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends in Immunology 2007 28 12 551 558 2-s2.0-36049034344 10.1016/j.it.2007.09.003 (Pubitemid 350101420)
23. Duan S. Z., Usher M. G., Mortensen R. M., Peroxisome proliferator- activated receptor- γ -mediated effects in the vasculature. Circulation Research 2008 102 3 283 294 2-s2.0-39449102532 10.1161/CIRCRESAHA.107.164384 (Pubitemid 351271648)
24. Ricote M., Li A. C., Willson T. M., Kelly C. J., Glass C. K., The peroxisome proliferator-activated receptor- γ is a negative regulator of macrophage activation. Nature 1998 391 6662 79 82 2-s2.0-0031886864 10.1038/34178 (Pubitemid 28079218)
25. Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J., Witztum J. L., Auwerx J., Palinski W., Glass C. K., Expression of the peroxisome proliferator-activated receptor γ (PPAR γ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proceedings of the National Academy of Sciences of the United States of America 1998 95 13 7614 7619 2-s2.0-0032560545
26. Gordon S., Alternative activation of macrophages. Nature Reviews Immunology 2003 3 1 23 35 2-s2.0-0037265240 10.1038/nri978 (Pubitemid 37328697)
27. Mosser D. M., Edwards J. P., Exploring the full spectrum of macrophage activation. Nature Reviews Immunology 2008 8 12 958 969 2-s2.0-56749174940 10.1038/nri2448
28. Stout R. D., Suttles J., Functional plasticity of macrophages: reversible adaptation to changing microenvironments. Journal of Leukocyte Biology 2004 76 3 509 513 2-s2.0-4344706372 10.1189/jlb.0504272 (Pubitemid 39129080)
29. Odegaard J. I., Ricardo-Gonzalez R. R., Goforth M. H., Morel C. R., Subramanian V., Mukundan L., Eagle A. R., Vats D., Brombacher F., Ferrante A. W., Chawla A., Macrophage-specific PPAR γ controls alternative activation and improves insulin resistance. Nature 2007 447 7148 1116 1120 2-s2.0-34347354309 10.1038/nature05894 (Pubitemid 47014427)
30. Jiang C., Ting A. T., Seed B., PPAR- γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998 391 6662 82 86 2-s2.0-0031888958 10.1038/34184 (Pubitemid 28079219)
31. Kintscher U., Goetze S., Wakino S., Kim S., Nagpal S., Chandraratna R. A. S., Graf K., Fleck E., Hsueh W. A., Law R. E., Peroxisome proliferator- activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. European Journal of Pharmacology 2000 401 3 259 270 2-s2.0-0034637218 10.1016/S0014-2999(00)00461-1 (Pubitemid 30608710)
32. Huang J. T., Welch J. S., Ricote M., Binder C. J., Willson T. M., Kelly C., Witztum J. L., Funk C. D., Conrad D., Glass C. K., Interleukin-4-dependent production of PPAR- γ ligands in macrophages by 12/15-lipoxygenase. Nature 1999 400 6742 378 382 2-s2.0-0033595261 10.1038/22572 (Pubitemid 29344205)
33. Vats D., Mukundan L., Odegaard J. I., Zhang L., Smith K. L., Morel C. R., Greaves D. R., Murray P. J., Chawla A., Oxidative metabolism and PGC-1 β attenuate macrophage-mediated inflammation. Cell Metabolism 2006 4 1 13 24 2-s2.0-33745428666 10.1016/j.cmet.2006.05.011 (Pubitemid 43942258)
34. Bouhlel M. A., Derudas B., Rigamonti E., Dièvart R., Brozek J., Haulon S., Zawadzki C., Jude B., Torpier G., Marx N., Staels B., Chinetti-Gbaguidi G., PPAR γ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metabolism 2007 6 2 137 143 2-s2.0-34547492488 10.1016/j.cmet.2007.06.010 (Pubitemid 47189091)
35. Tontonoz P., Nagy L., Alvarez J. G. A., Thomazy V. A., Evans R. M., PPAR γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998 93 2 241 252 2-s2.0-0032540012 10.1016/S0092-8674(00)81575-5 (Pubitemid 28180857)
36. Nagy L., Tontonoz P., Alvarez J. G. A., Chen H., Evans R. M., Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR γ Cell 1998 93 2 229 240 2-s2.0-0032540325 10.1016/S0092-8674(00)81574-3 (Pubitemid 28180856)
37. Kavanagh I. C., Symes C. E., Renaudin P., Nova E., Mesa M. D., Boukouvalas G., Leake D. S., Yaqoob P., Degree of oxidation of low density lipoprotein affects expression of CD36 and PPAR γ but not cytokine production, by human monocyte-macrophages. Atherosclerosis 2003 168 2 271 282 2-s2.0-0037497959 10.1016/S0021-9150(03)00148-5 (Pubitemid 36703326)
38. Westendorf T., Graessler J., Kopprasch S., Hypochlorite-oxidized low-density lipoprotein upregulates CD36 and PPAR γ mRNA expression and modulates SR-BI gene expression in murine macrophages. Molecular and Cellular Biochemistry 2005 277 1-2 143 152 2-s2.0-24144457806 10.1007/s11010-005-5873-z (Pubitemid 41236197)
39. Chawla A., Boisvert W. A., Lee C. H., Laffitte B. A., Barak Y., Joseph S. B., Liao D., Nagy L., Edwards P. A., Curtiss L. K., Evans R. M., Tontonoz P., A PPAR γ -LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Molecular Cell 2001 7 1 161 171 2-s2.0-17744376173 10.1016/S1097-2765(01)00164-2 (Pubitemid 32162909)
40. Chinetti G., Lestavel S., Bocher V., Remaley A. T., Neve B., Torra I. P., Teissier E., Minnich A., Jaye M., Duverger N., Brewer H. B., Fruchart J. C., Clavey V., Staels B., PPAR- α and PPAR- γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine 2001 7 1 53 58 2-s2.0-0035138625 10.1038/83348 (Pubitemid 32095642)
41. Cunard R., Ricote M., DiCampli D., Archer D. C., Kahn D. A., Glass C. K., Kelly C. J., Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. Journal of Immunology 2002 168 6 2795 2802 2-s2.0-0037087324 (Pubitemid 34211658)
42. Yang X. Y., Wang L. H., Chen T., Hodge D. R., Resau J. H., DaSilva L., Farrar W. L., Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor γ (PPAR γ) agonists. PPAR γ co-association with transcription factor NFAT. The Journal of Biological Chemistry 2000 275 7 4541 4544 2-s2.0-0001297403 10.1074/jbc.275.7.4541 (Pubitemid 30108833)
43. Clark R. B., Bishop-Bailey D., Estrada-Hernandez T., Hla T., Puddington L., Padula S. J., The nuclear receptor PPAR γ and immunoregulation: PPAR γ mediates inhibition of helper T cell responses. Journal of Immunology 2000 164 3 1364 1371 2-s2.0-0034141545 (Pubitemid 30067250)
44. Marx N., Kehrle B., Kohlhammer K., Grüb M., Koenig W., Hombach V., Libby P., Plutzky J., PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circulation Research 2002 90 6 703 710 2-s2.0-0037023635 10.1161/01.RES.0000014225.20727.8F (Pubitemid 34640890)
45. Saubermann L. J., Nakajima A., Wada K., Zhao S., Terauchi Y., Kadowaki T., Aburatani H., Matsuhashi N., Nagai R., Blumberg R. S., Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflammatory Bowel Diseases 2002 8 5 330 339 2-s2.0-0036743165
46. Klotz L., Burgdorf S., Dani I., Saijo K., Flossdorf J., Hucke S., Alferink J., Novak N., Beyer M., Mayer G., Langhans B., Klockgether T., Waisman A., Eberl G., Schultze J., Famulok M., Kolanus W., Glass C., Kurts C., Knolle P. A., The nuclear receptor PPAR γ selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. The Journal of Experimental Medicine 2009 206 10 2079 2089 2-s2.0-70350459594 10.1084/jem.20082771
47. George J., Mechanisms of Disease: the evolving role of regulatory T cells in atherosclerosis. Nature Clinical Practice Cardiovascular Medicine 2008 5 9 531 540 2-s2.0-50649124207 10.1038/ncpcardio1279
48. Wohlfert E. A., Nichols F. C., Nevius E., Clark R. B., Peroxisome proliferator-activated receptor γ (PPAR γ) and immunoregulation: enhancement of regulatory T cells through PPAR γ-dependent and -independent mechanisms. Journal of Immunology 2007 178 7 4129 4135 2-s2.0-33947615887 (Pubitemid 46492362)
49. + regulatory T cells. Journal of Immunology 2010 185 12 7186 7198 2-s2.0-78650642538 10.4049/jimmunol.1001437
50. Kyaw T., Tipping P., Toh B. H., Bobik A., Current understanding of the role of B cell subsets and intimal and adventitial B cells in atherosclerosis. Current Opinion in Lipidology 2011 22 5 373 379 10.1097/MOL.0b013e32834adaf3
51. Lebien T. W., Tedder T. F., B lymphocytes: how they develop and function. Blood 2008 112 5 1570 1580 2-s2.0-47249099558 10.1182/blood-2008-02-078071
52. Galkina E., Ley K., Immune and inflammatory mechanisms of atherosclerosis. Annual Review of Immunology 2009 27 165 197 2-s2.0-67650720510 10.1146/annurev.immunol.021908.132620
53. Binder C. J., Natural IgM antibodies against oxidation-specific epitopes. Journal of Clinical Immunology 2010 30 1 S56 S60 2-s2.0-77956181462 10.1007/s10875-010-9396-3
54. Harris D. P., Haynes L., Sayles P. C., Duso D. K., Eaton S. M., Lepak N. M., Johnson L. L., Swain S. L., Lund F. E., Reciprocal regulation of polarized cytokine production by effector B and T cells. Nature Immunology 2000 1 6 475 482 2-s2.0-0034568991
55. Mizoguchi A., Bhan A. K., A case for regulatory B cells. Journal of Immunology 2006 176 2 705 710 2-s2.0-30744458329 (Pubitemid 43099663)
56. Serra P., Santamaria P., To B regulated: B cells as members of the regulatory workforce. Trends in Immunology 2006 27 1 7 10 2-s2.0-30544438882 10.1016/j.it.2005.11.003 (Pubitemid 43083558)
57. Bouaziz J. D., Yanaba K., Tedder T. F., Regulatory B cells as inhibitors of immune responses and inflammation. Immunological Reviews 2008 224 1 201 214 2-s2.0-49249136452 10.1111/j.1600-065X.2008.00661.x
58. Lund F. E., Cytokine-producing B lymphocyteskey regulators of immunity. Current Opinion in Immunology 2008 20 3 332 338 2-s2.0-45449099469 10.1016/j.coi.2008.03.003
59. Mauri C., Ehrenstein M. R., The short history of regulatory B cells. Trends in Immunology 2008 29 1 34 40 2-s2.0-37849044394 10.1016/j.it.2007.10.004
60. 2 induce apoptosis in normal and malignant B-lineage cells. Journal of Immunology 2000 165 12 6941 6948 2-s2.0-0034672055 (Pubitemid 32001165)
61. Padilla J., Leung E., Phipps R. P., Human B lymphocytes and B lymphomas express PPAR- γ and are killed by PPAR- γ agonists. Clinical Immunology 2002 103 1 22 33 2-s2.0-0036245961 10.1006/clim.2001.5181 (Pubitemid 34478417)
62. Schlezinger J. J., Jensen B. A., Mann K. K., Ryu H. Y., Sherr D. H., Peroxisome proliferator-activated receptor γ -mediated NF- κ B activation and apoptosis in pre-B cells. Journal of Immunology 2002 169 12 6831 6841 2-s2.0-0037114137 (Pubitemid 36899268)
63. 2 Journal of Immunology 2004 173 5 3165 3177 2-s2.0-4344607441 (Pubitemid 39142023)
64. 2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF- κ B activity and down-regulation of antiapoptotic proteins. Blood 2005 105 4 1750 1758 2-s2.0-13544263219 10.1182/blood-2004-04-1360 (Pubitemid 40223699)
65. Ray D. M., Akbiyik F., Bernstein S. H., Phipps R. P., CD40 engagement prevents peroxisome proliferator-activated receptor γ agonist-induced apoptosis of B lymphocytes and B lymphoma cells by an NF- κ B-dependent mechanism. Journal of Immunology 2005 174 7 4060 4069 2-s2.0-15444369546 (Pubitemid 40395982)
66. Schlezinger J. J., Emberley J. K., Sherr D. H., Activation of multiple mitogen-activated protein kinases in pro/pre-B cells by GW7845, a peroxisome proliferator-activated receptor γ agonist, and their contribution to GW7845-induced apoptosis. Toxicological Sciences 2006 92 2 433 444 2-s2.0-33745798598 10.1093/toxsci/kfl003 (Pubitemid 44018960)
67. Garcia-Bates T. M., Baglole C. J., Bernard M. P., Murant T. I., Simpson-Haidaris P. J., Phipps R. P., Peroxisome proliferator-activated receptor γ ligands enhance human B cell antibody production and differentiation. Journal of Immunology 2009 183 11 6903 6912 2-s2.0-73349104435 10.4049/jimmunol.0900324
68. Koltsova E. K., Ley K., How dendritic cells shape atherosclerosis. Trends in Immunology 2011 32 11 540 547 10.1016/j.it.2011.07.001
69. Manthey H. D., Zernecke A., Dendritic cells in atherosclerosis: functions in immune regulation and beyond. Thrombosis and Haemostasis 2011 106 5 772 778 10.1160/TH11-05-0296
70. van Vre E. A., van Brussel I., Bosmans J. M., Vrints C. J., Bult H., Dendritic cells in human atherosclerosis: from circulation to atherosclerotic plaques. Mediators of Inflammation 2011 2011 13 941396 10.1155/2011/941396
71. Galkina E., Kadl A., Sanders J., Varughese D., Sarembock I. J., Ley K., Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. The Journal of Experimental Medicine 2006 203 5 1273 1282 2-s2.0-33646692002 10.1084/jem.20052205 (Pubitemid 43736596)
72. Liu P., Yu Y. R. A., Spencer J. A., Johnson A. E., Vallanat C. T., Fong A. M., Patterson C., Patel D. D., CX3CR1 deficiency impairs dendritic cell accumulation in arterial intima and reduces atherosclerotic burden. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 2 243 250 2-s2.0-38549149964 10.1161/ATVBAHA.107.158675 (Pubitemid 351161195)
73. Weber C., Meiler S., Döring Y., Koch M., Drechsler M., Megens R. T. A., Rowinska Z., Bidzhekov K., Fecher C., Ribechini E., van Zandvoort M. A. M. J., Binder C. J., Jelinek I., Hristov M., Boon L., Jung S., Korn T., Lutz M. B., Förster I., Zenke M., Hieronymus T., Junt T., Zernecke A., CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. Journal of Clinical Investigation 2011 121 7 2898 2910 2-s2.0-79960020852 10.1172/JCI44925
74. Yilmaz A., Lochno M., Traeg F., Cicha I., Reiss C., Stumpf C., Raaz D., Anger T., Amann K., Probst T., Ludwig J., Daniel W. G., Garlichs C. D., Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 2004 176 1 101 110 2-s2.0-4043114983 10.1016/j.atherosclerosis.2004.04.027 (Pubitemid 39078651)
75. Bobryshev Y. V., Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. European Heart Journal 2005 26 17 1700 1704 2-s2.0-24044553923 10.1093/eurheartj/ehi282 (Pubitemid 41219842)
76. Erbel C., Sato K., Meyer F. B., Kopecky S. L., Frye R. L., Goronzy J. J., Weyand C. M., Functional profile of activated dendritic cells in unstable atherosclerotic plaque. Basic Research in Cardiology 2007 102 2 123 132 2-s2.0-33846677469 10.1007/s00395-006-0636-x (Pubitemid 46189953)
77. Steinman R. M., Hemmi H., Dendritic cells: translating innate to adaptive immunity. Current Topics in Microbiology and Immunology 2006 311 17 58 2-s2.0-33750934617 (Pubitemid 47413194)
78. Jongstra-Bilen J., Haidari M., Zhu S. N., Chen M., Guha D., Cybulsky M. I., Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. The Journal of Experimental Medicine 2006 203 9 2073 2083 2-s2.0-33748469407 10.1084/jem.20060245 (Pubitemid 44352229)
79. Shaposhnik Z., Wang X., Weinstein M., Bennett B. J., Lusis A. J., Granulocyte macrophage colony-stimulating factor regulates dendritic cell content of atherosclerotic lesions. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 3 621 627 2-s2.0-33847080411 10.1161/01.ATV.0000254673.55431.e6
80. Zhu S. N., Chen M., Jongstra-Bilen J., Cybulsky M. I., GM-CSF regulates intimal cell proliferation in nascent atherosclerotic lesions. The Journal of Experimental Medicine 2009 206 10 2141 2149 2-s2.0-70350455635 10.1084/jem.20090866
81. Paulson K. E., Zhu S. N., Chen M., Nurmohamed S., Jongstra-Bilen J., Cybulsky M. I., Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. Circulation Research 2010 106 2 383 390 2-s2.0-76349096459 10.1161/CIRCRESAHA.109.210781
82. Miller Y. I., Choi S. H., Wiesner P., Fang L., Harkewicz R., Hartvigsen K., Boullier A., Gonen A., Diehl C. J., Que X., Montano E., Shaw P. X., Tsimikas S., Binder C. J., Witztum J. L., Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circulation Research 2011 108 2 235 248 2-s2.0-79251580687 10.1161/CIRCRESAHA.110.223875
83. Faveeuw C., Fougeray S., Angeli V., Fontaine J., Chinetti G., Gosset P., Delerive P., Maliszewski C., Capron M., Staels B., Moser M., Trottein F., Peroxisome proliferator-activated receptor γ activators inhibit interleukin-12 production in murine dendritic cells. FEBS Letters 2000 486 3 261 266 2-s2.0-0034672472 10.1016/S0014-5793(00)02319-X
84. Gosset P., Charbonnier A. S., Delerive P., Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. European Journal of Immunology 2001 31 10 2857 2865 10.1002/1521-4141(2001010)31:10<2857::AID-IMMU2857>3.0.CO;2- X (Pubitemid 32994536)
85. Nencioni A., Grünebach F., Zobywlaski A., Denzlinger C., Brugger W., Brossart P., Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor γ Journal of Immunology 2002 169 3 1228 1235 2-s2.0-0036681640 (Pubitemid 34809163)
86. Jakobsen M. A., Petersen R. K., Kristiansen K., Lange M., Lillevang S. T., Peroxisome proliferator-activated receptor α δ γ 1 and γ 2 expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands. Scandinavian Journal of Immunology 2006 63 5 330 337 2-s2.0-33646262056 10.1111/j.1365-3083.2006.01745.x
87. Szatmari I., Rajnavolgyi E., Nagy L., PPAR γ a lipid-activated transcription factor as a regulator of dendritic cell function. Annals of the New York Academy of Sciences 2006 1088 207 218 2-s2.0-34447627877 10.1196/annals.1366.013 (Pubitemid 47092034)
88. + T cell anergy. Journal of Immunology 2007 178 4 2122 2231
89. Szatmari I., Töröcsik D., Agostini M., Nagy T., Gurnell M., Barta E., Chatterjee K., Nagy L., PPAR γ regulates the function of human dendritic cells primarily by altering lipid metabolism. Blood 2007 110 9 3271 3280 2-s2.0-36148982257 10.1182/blood-2007-06-096222 (Pubitemid 350106320)
90. Zapata-Gonzalez F., Rueda F., Petriz J., Domingo P., Villarroya F., de Madariaga A., Domingo J. C., 9-cis-Retinoic Acid (9cRA), a Retinoid X Receptor (RXR) ligand, exerts immunosuppressive effects on dendritic cells by RXR-dependent activation: inhibition of peroxisome proliferator-activated receptor γ blocks some of the 9cRA activities, and precludes them to mature phenotype development. Journal of Immunology 2007 178 10 6130 6139 2-s2.0-34248169760 (Pubitemid 46717394)
91. Drechsler M., Doring Y., Megens R. T., Soehnlein O., Neutrophilic granulocytespromiscuous accelerators of atherosclerosis. Thrombosis and Haemostasis 2011 106 5 839 848 10.1160/TH11-07-0501
92. Weber C., Noels H., Atherosclerosis: current pathogenesis and therapeutic options. Nature Medicine 2011 17 11 1410 1422 10.1038/nm.2538
93. Weber C., Zernecke A., Libby P., The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nature Reviews Immunology 2008 8 10 802 815 2-s2.0-52949118482 10.1038/nri2415
94. Zernecke A., Bot I., Djalali-Talab Y., Shagdarsuren E., Bidzhekov K., Meiler S., Krohn R., Schober A., Sperandio M., Soehnlein O., Bornemann J., Tacke F., Biessen E. A., Weber C., Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circulation Research 2008 102 2 209 217 2-s2.0-41149085145 10.1161/CIRCRESAHA.107.160697 (Pubitemid 351651125)
95. -/- mice. The American Journal of Pathology 2010 177 1 493 500 2-s2.0-77954583040 10.2353/ajpath.2010.090480
96. Drechsler M., Megens R. T. A., van Zandvoort M., Weber C., Soehnlein O., Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010 122 18 1837 1845 2-s2.0-78349304885 10.1161/CIRCULATIONAHA.110. 961714
97. Soehnlein O., Lindbom L., Phagocyte partnership during the onset and resolution of inflammation. Nature Reviews Immunology 2010 10 6 427 439 2-s2.0-77952865796 10.1038/nri2779
98. Greene M. E., Blumberg B., McBride O. W., Yi H. F., Kronquist K., Kwan K., Hsieh L., Greene G., Nimer S. D., isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expression 1995 4 4-5 281 299 2-s2.0-0029152375
99. 2 inhibits the β 2 integrin- dependent oxidative burst: involvement of a mechanism distinct from peroxisome proliferator-activated receptor γ ligation. Journal of Immunology 1999 163 11 6187 6192 2-s2.0-0033248121
100. Birrell M. A., Patel H. J., McCluskie K., Wong S., Leonard T., Yacoub M. H., Belvisi M. G., PPAR- γ agonists as therapy for diseases involving airway neutrophilia. European Respiratory Journal 2004 24 1 18 23 2-s2.0-3543104442 10.1183/09031936.04.00098303 (Pubitemid 39029065)
101. Imamoto E., Yoshida N., Uchiyama K., Kuroda M., Kokura S., Ichikawa H., Naito Y., Tanigawa T., Yoshikawa T., Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells. BioFactors 2004 20 1 37 47 2-s2.0-2342461706 (Pubitemid 38586208)
102. Liu D., Zeng B. X., Zhang S. H., Yao S. L., Rosiglitazone, an agonist of peroxisome proliferator-activated receptor γ reduces pulmonary inflammatory response in a rat model of endotoxemia. Inflammation Research 2005 54 11 464 470 2-s2.0-28044431614 10.1007/s00011-005-1379-0 (Pubitemid 41690375)
103. Sánchez-Hidalgo M., Martín A. R., Villegas I., Alarcón De La Lastra C., Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochemical Pharmacology 2005 69 12 1733 1744 2-s2.0-20344363144 10.1016/j.bcp.2005.03.024 (Pubitemid 40780073)
104. 2 reduces neutrophil migration via a nitric oxide pathway. Journal of Immunology 2008 180 1 609 617 2-s2.0-40449084265
105. Singh S., Loke Y. K., Furberg C. D., Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. Journal of the American Medical Association 2007 298 10 1189 1195 2-s2.0-34548580881 10.1001/jama.298.10.1189 (Pubitemid 47403105)
106. Nissen S. E., Wolski K., Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Archives of Internal Medicine 2010 170 14 1191 1201 2-s2.0-77955285732 10.1001/archinternmed.2010.207
107. Lincoff A. M., Wolski K., Nicholls S. J., Nissen S. E., Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. Journal of the American Medical Association 2007 298 10 1180 1188 2-s2.0-34548590934 10.1001/jama.298.10.1180 (Pubitemid 47403104)
108. Singh S., Loke Y. K., Furberg C. D., Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007 30 8 2148 2153 2-s2.0-34547700735 10.2337/dc07-0141 (Pubitemid 47219440)
109. Loke Y. K., Kwok C. S., Singh S., Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. British Medical Journal 2011 342 d1309 2-s2.0-79954988778 10.1136/bmj.d1309
110. Cohen D., Insiders criticise FDA's decision not to withdraw rosiglitazone. British Medical Journal 2010 341 c5333 2-s2.0-77957370174 10.1136/bmj.c5333